BioPharmSignal logoBioPharmSignal

Biotech News

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Lineage Cell Therapeutics (LCTX)Lineage Cell Therapeutics2026-06-25 13:46 ESTCommercial

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted 10-Year CAGR of 7.7% CARLSBAD, Calif. --(BUSINESS WIRE)--Mar.

Open original release

Related news

LCTXLineage Cell Therapeutics2026-07-06 12:00 EST

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

LCTXLineage Cell Therapeutics2026-06-25 13:46 EST

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-06-25 13:46 EST

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-06-25 13:46 EST

Lineage Achieves First Milestone Under Worldwide Collaboration Agreement with Genentech

LCTXLineage Cell Therapeutics2026-06-25 13:46 EST

Lineage Cell Therapeutics Issues Letter to Stockholders

LCTXLineage Cell Therapeutics2026-06-25 13:46 EST

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

LCTXLineage Cell Therapeutics2026-06-25 13:46 EST

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

LCTXLineage Cell Therapeutics2026-06-25 13:46 EST

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-06-25 13:46 EST

Lineage Announces Formation of Scientific Advisory Board

LCTXLineage Cell Therapeutics2026-06-25 13:46 EST

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

View all latest news

Lineage Cell Therapeutics

Lineage Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.

Recent company news

LCTXZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

LCTXZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

LCTXBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

LCTXGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

LCTXMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
1.21 USD
Market cap
319.1M USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States